Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.

Based on the clinical data demonstrating that there was no apparent nonlinearity in exposure after multiple dosing of brigatinib in patients over a dose range of 60–240 mg 2 and there was a less than 25% increase in the C max of brigatinib after co‐administration with the P‐gp inhibitor itraconazole, 15 it was postulated that the contribution of P‐gp‐ or BCRP‐mediated efflux of brigatinib in vivo may not be significant.

also in 2,774 other papers